Healthcare provider profile · identity verified

Hardeep Chohan, MD

Internal Medicine · CLOVIS, CA · NPI 1104904002

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	495	191
Lisinopril	Lisinopril	310	122
Amlodipine Besylate	Amlodipine Besylate	298	108
Levothyroxine Sodium	Levothyroxine Sodium	236	85
Albuterol Sulfate Hfa	Albuterol Sulfate	198	87
Tamsulosin Hcl	Tamsulosin Hcl	193	70
Famotidine	Famotidine	189	69
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	185	33
Losartan Potassium	Losartan Potassium	182	71
Fluticasone Propionate	Fluticasone Propionate	155	70
Omeprazole	Omeprazole	145	49
Tizanidine Hcl	Tizanidine Hcl	139	52
Atenolol	Atenolol	138	50
Hydrochlorothiazide	Hydrochlorothiazide	138	52
Pantoprazole Sodium	Pantoprazole Sodium	136	52
Gabapentin	Gabapentin	131	52
Metoprolol Succinate	Metoprolol Succinate	124	50
Prednisone	Prednisone	119	93
Metformin Hcl Er	Metformin Hcl	113	41
Metformin Hcl	Metformin Hcl	107	42
Simvastatin	Simvastatin	107	33
Alendronate Sodium	Alendronate Sodium	98	32
Meloxicam	Meloxicam	97	33
Furosemide	Furosemide	94	38
Glipizide	Glipizide	94	39
Metoprolol Tartrate	Metoprolol Tartrate	92	34
Montelukast Sodium	Montelukast Sodium	89	34
Duloxetine Hcl	Duloxetine Hcl	85	25
Baclofen	Baclofen	84	19
Potassium Chloride	Potassium Chloride	81	29
Doxycycline Monohydrate	Doxycycline Monohydrate	77	66
Trazodone Hcl	Trazodone Hcl	77	25
Clopidogrel	Clopidogrel Bisulfate	73	22
Ibuprofen	Ibuprofen	72	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	23
Allopurinol	Allopurinol	68	24
Wixela Inhub	Fluticasone Propion/Salmeterol	68	29
Rosuvastatin Calcium	Rosuvastatin Calcium	66	28
Trospium Chloride	Trospium Chloride	61	21
Finasteride	Finasteride	59	21
Hydralazine Hcl	Hydralazine Hcl	59	23
Cefpodoxime Proxetil	Cefpodoxime Proxetil	58	48
Lovastatin	Lovastatin	58	20
Ondansetron Odt	Ondansetron	53	15
Alprazolam	Alprazolam	51	14
Carvedilol	Carvedilol	51	19
Pravastatin Sodium	Pravastatin Sodium	50	19
Alvesco	Ciclesonide	49	23
Ozempic	Semaglutide	48	suppressed
Pregabalin	Pregabalin	47	suppressed
Tramadol Hcl	Tramadol Hcl	46	13
Terazosin Hcl	Terazosin Hcl	45	15
Jardiance	Empagliflozin	44	17
Ropinirole Hcl	Ropinirole Hcl	43	16
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	37
Glipizide Er	Glipizide	40	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	40	14
Fluoxetine Hcl	Fluoxetine Hcl	39	13
Temazepam	Temazepam	39	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Lorazepam	Lorazepam	37	suppressed
Sertraline Hcl	Sertraline Hcl	35	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	34	14
Pradaxa	Dabigatran Etexilate Mesylate	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	32	24
Propranolol Hcl	Propranolol Hcl	31	suppressed
Fenofibrate	Fenofibrate	29	suppressed
Humulin N	Insulin Nph Human Isophane	27	11
Nortriptyline Hcl	Nortriptyline Hcl	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	26	26
Breyna	Budesonide/Formoterol Fumarate	26	11
Spiriva Respimat	Tiotropium Bromide	26	12
Clonidine Hcl	Clonidine Hcl	24	11
Sucralfate	Sucralfate	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	23	suppressed
Acyclovir	Acyclovir	22	11
Lactulose	Lactulose	21	suppressed
Azithromycin	Azithromycin	20	17
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	20	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	20	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	20	suppressed
Spironolactone	Spironolactone	19	11
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Nabumetone	Nabumetone	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Amoxicillin	Amoxicillin	17	11
Colchicine	Colchicine	17	suppressed
Digoxin	Digoxin	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	17
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Clonazepam	Clonazepam	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Topiramate	Topiramate	15	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Bumetanide	Bumetanide	12	suppressed
Morphine Sulfate Er	Morphine Sulfate	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	12	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Ofloxacin	Ofloxacin	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error